HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
KRYS [NASD]
Krystal Biotech, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-5.50 Insider Own13.70% Shs Outstand25.68M Perf Week2.79%
Market Cap2.04B Forward P/E- EPS next Y-2.56 Insider Trans-6.66% Shs Float20.57M Perf Month-2.15%
Income-140.00M PEG- EPS next Q-1.51 Inst Own82.30% Short Float / Ratio5.56% / 5.74 Perf Quarter0.20%
Sales- P/S- EPS this Y-75.20% Inst Trans0.29% Short Interest1.14M Perf Half Y13.46%
Book/sh20.33 P/B3.94 EPS next Y12.40% ROA-23.80% Target Price114.12 Perf Year19.67%
Cash/sh14.85 P/C5.39 EPS next 5Y- ROE-25.80% 52W Range47.67 - 89.59 Perf YTD1.06%
Dividend- P/FCF- EPS past 5Y-48.20% ROI- 52W High-10.64% Beta0.86
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low67.95% ATR3.28
Employees210 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)56.93 Volatility3.12% 4.53%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.20% Profit Margin- Rel Volume1.76 Prev Close79.35
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume199.13K Price80.06
Recom1.80 SMA204.90% SMA502.15% SMA2007.99% Volume349,740 Change0.89%
Feb-28-23Upgrade Goldman Neutral → Buy $79 → $124
Aug-25-22Downgrade Goldman Buy → Neutral $74
Jan-18-22Initiated BofA Securities Buy $110
Jul-20-21Upgrade Goldman Neutral → Buy $73 → $90
Sep-18-20Initiated B. Riley FBR Buy $100
Jun-04-20Initiated Evercore ISI Outperform $90
Sep-24-19Initiated Goldman Neutral $60
Aug-06-19Reiterated H.C. Wainwright Buy $56 → $59
Jun-24-19Reiterated H.C. Wainwright Buy $38 → $56
Jun-24-19Reiterated Chardan Capital Markets Buy $57.50 → $75
Show Previous Ratings
Mar-06-23 08:09PM
Goldman Sachs Sees Over 60% Upside in These 3 Lesser-Known Stocks Heres Why They Could Jump
TipRanks
07:00AM
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
GlobeNewswire
Mar-03-23 06:38AM
Daily Vickers Top Buyers & Sellers for 03/03/2023
Argus Research
Mar-02-23 07:00AM
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
GlobeNewswire
Feb-27-23 07:00AM
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
GlobeNewswire
11:14AM Loading…
Feb-21-23 11:14AM
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Simply Wall St.
Jan-18-23 07:00AM
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
GlobeNewswire
Jan-09-23 03:34PM
Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA
American City Business Journals -10.91%
08:58AM
Krystal Biotechs stock is down on delayed PDUFA date
MarketWatch
08:00AM
Krystal Biotech Announces FDAs 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
GlobeNewswire
Dec-18-22 06:21PM
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
InvestorPlace
Dec-16-22 02:24AM
BofA Securities: The most promising biotech stocks in 2023
Investing.com
Dec-15-22 09:07AM
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
Benzinga
Dec-14-22 05:00PM
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
GlobeNewswire +5.10%
Dec-12-22 03:44PM
12 Best Small-Cap Healthcare Stocks To Buy Now
Insider Monkey
10:07AM Loading…
Dec-06-22 10:07AM
2 Risky Stocks That Could Soar in 2023
Motley Fool
Dec-05-22 07:00AM
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
GlobeNewswire
Dec-01-22 07:00AM
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
GlobeNewswire
Nov-23-22 07:00AM
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
GlobeNewswire
Nov-17-22 09:07AM
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles
Benzinga
07:00AM
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
GlobeNewswire
Nov-07-22 07:00AM
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
GlobeNewswire +6.61%
Sep-29-22 07:00AM
Krystal Biotech to Present at Chardans 6th Annual Genetic Medicines Conference
GlobeNewswire
Sep-21-22 04:30PM
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire
Sep-19-22 10:10AM
2 Growth Stocks That Could Double in the Next Year
Motley Fool
Sep-14-22 11:22AM
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Simply Wall St.
Sep-08-22 07:00AM
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewswire
Aug-19-22 01:27PM
FDA reviewing Krystal Biotech's biologics application
American City Business Journals
Aug-18-22 05:00PM
FDA Accepts Krystal Biotechs Biologics License Application for Dystrophic Epidermolysis Bullosa
GlobeNewswire
Aug-08-22 07:00AM
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
GlobeNewswire
06:39PM Loading…
Aug-01-22 06:39PM
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
GlobeNewswire
07:00AM
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
GlobeNewswire
Jul-30-22 07:50AM
Can This Healthcare Stock Keep Beating the Market?
Motley Fool
Jul-06-22 07:00AM
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
GlobeNewswire
Jun-22-22 09:57AM
Krystal Biotech applies for biologics license for gene therapy
American City Business Journals +6.81%
07:00AM
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
GlobeNewswire
Jun-09-22 09:57AM
Steve Cohen Is Holding These 10 Tech Stocks Despite Selloff
Insider Monkey
Jun-07-22 07:00AM
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
GlobeNewswire
May-23-22 03:27PM
Krystal Biotech Stock Flashes Renewed Technical Strength
Investor's Business Daily
May-19-22 07:30PM
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
GlobeNewswire
May-09-22 05:35PM
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
Zacks -12.28%
May-03-22 07:00AM
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
GlobeNewswire
Apr-28-22 07:00AM
Jeune Aesthetics Announces Formation and Members of Scientific Advisory Board
GlobeNewswire
Apr-14-22 02:43PM
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
Investor's Business Daily
Apr-11-22 07:00AM
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
GlobeNewswire
Apr-07-22 09:47AM
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Simply Wall St.
Mar-28-22 11:00AM
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
GlobeNewswire
Mar-26-22 12:00PM
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
GlobeNewswire
Mar-24-22 07:00AM
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
GlobeNewswire
Mar-22-22 08:30AM
10 Healthcare Stocks to Buy Today According to Steven Cohens Point72 Asset Management
Insider Monkey
Mar-18-22 07:00AM
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
GlobeNewswire
Mar-15-22 11:07AM
Two Pittsburgh biotech firms settle trade-secret lawsuit
American City Business Journals
07:00AM
Krystal Biotech Announces Settlement with PeriphaGen, Inc.
GlobeNewswire
Feb-28-22 07:00AM
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
GlobeNewswire
Feb-24-22 07:00AM
Krystal Biotech to Participate in Cowens 42nd Annual Health Care Conference
GlobeNewswire +5.26%
Feb-03-22 05:38PM
Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...
GuruFocus.com
Feb-02-22 06:40AM
2 Biotech Stocks That Could Skyrocket This Year
Motley Fool -5.15%
Jan-18-22 07:00AM
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
GlobeNewswire
Jan-07-22 06:39AM
Do Insiders Own Lots Of Shares In Krystal Biotech, Inc. (NASDAQ:KRYS)?
Simply Wall St.
Jan-06-22 09:38AM
Tarbox Family Office, Inc. Buys iShares Core Total USD Bond Market ETF, iShares Core MSCI Total ...
GuruFocus.com
Dec-15-21 07:17AM
Could This Soaring Biotech Stock Make You Rich?
Motley Fool
Dec-03-21 02:35AM
Krystal: Impressive DEB Clincal Trial Results Merit a New Price Target
TipRanks
Dec-02-21 06:47PM
Why Krystal Biotech's Shares Rose More Than 77% This Week
Motley Fool
Dec-01-21 01:51PM
Why Krystal Biotech Stock Is Retreating Today
Motley Fool -13.49%
Nov-30-21 08:15PM
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
GlobeNewswire -8.71%
09:37AM
Company News for Nov 30, 2021
Zacks
Nov-29-21 04:33PM
First Gene Therapy for Skin, From Krystal, Heals Wounded Kids
Barrons.com +121.65%
04:20PM
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
GlobeNewswire
11:50AM
KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% Today
InvestorPlace
08:48AM
5 Top Stock Gainers for Monday: Zscaler, Krystal Biotech, Adagio
TheStreet.com
07:00AM
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
GlobeNewswire
05:43AM
Krystal Biotech Shares More Than Double After Positive VYJUVEK Trial Results
Investing.com
Nov-19-21 07:00AM
Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting
GlobeNewswire
Nov-08-21 02:16PM
Krystal's new Pittsburgh gene therapy center to be operational in 2022
American City Business Journals
07:00AM
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
GlobeNewswire
Nov-05-21 08:36PM
Gene Therapy Is a Huge Opportunity. It Pays to be Patient.
Barrons.com
03:30AM
Testing May Take Awhile, but Gene Therapy Is Poised to Tackle Mass Diseases
Barrons.com
Oct-26-21 07:00AM
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire
Oct-19-21 04:05PM
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
GlobeNewswire
Oct-14-21 07:00AM
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
GlobeNewswire
Oct-12-21 08:00AM
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)
GlobeNewswire
Oct-01-21 04:01PM
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
GlobeNewswire
Sep-29-21 08:00AM
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
GlobeNewswire
Sep-15-21 08:00AM
Krystal Biotech Appoints Laurent Goux as General Manager of Europe
GlobeNewswire
Sep-09-21 08:00AM
Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021
GlobeNewswire
Sep-07-21 04:31PM
Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire
Aug-09-21 08:00AM
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress
GlobeNewswire
04:41AM
Krystal Biotech (NASDAQ:KRYS) Is In A Good Position To Deliver On Growth Plans
Simply Wall St.
Jul-02-21 07:43AM
Krystal Biotech's KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition
Benzinga
Jul-01-21 04:15PM
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
GlobeNewswire +5.54%
Jun-08-21 09:04AM
New Strong Sell Stocks for June 8th
Zacks
Jun-03-21 08:00AM
Krystal Biotech to Participate in Upcoming Investor Conferences
GlobeNewswire
May-28-21 11:35AM
New Strong Sell Stocks for May 28th
Zacks
May-21-21 09:09AM
New Strong Sell Stocks for May 21st
Zacks
May-10-21 08:00AM
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress
GlobeNewswire -6.91%
May-03-21 08:00AM
Krystal Biotech Appoints Andy Orth as Chief Commercial Officer
GlobeNewswire
Apr-29-21 05:41PM
Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory
Investor's Business Daily
Apr-27-21 04:35PM
Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT
GlobeNewswire
Apr-26-21 04:05PM
Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
GlobeNewswire
Apr-19-21 08:00AM
Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
GlobeNewswire
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSSI DINO ADirectorMar 01Sale83.2540,0003,329,97283,691Mar 02 05:05 PM
Krishnan Krish SPresident and CEOJan 18Sale80.982,852230,9551,677,263Jan 19 05:43 PM
Krishnan SumaPresident, R&DJan 18Sale80.982,852230,9551,677,263Jan 19 05:44 PM
Krishnan SumaPresident, R&DJan 18Sale80.982,851230,8741,738,688Jan 19 05:44 PM
Krishnan Krish SPresident and CEOJan 18Sale80.982,851230,8741,738,688Jan 19 05:43 PM
Krishnan Krish SPresident and CEOJan 17Sale80.7722,1491,788,9981,741,539Jan 19 05:43 PM
Krishnan SumaPresident, R&DJan 17Sale80.7722,1491,788,9981,741,539Jan 19 05:44 PM
Krishnan SumaPresident, R&DJan 17Sale80.7722,1481,788,9161,680,115Jan 19 05:44 PM
Krishnan Krish SPresident and CEOJan 17Sale80.7722,1481,788,9161,680,115Jan 19 05:43 PM
Krishnan SumaPresident, R&DJan 04Sale80.093,938315,3851,702,263Jan 05 06:10 PM
Krishnan Krish SPresident and CEOJan 04Sale80.093,938315,3851,702,263Jan 05 06:08 PM
Krishnan SumaPresident, R&DJan 04Sale80.083,748300,1401,763,688Jan 05 06:10 PM
Krishnan Krish SPresident and CEOJan 04Sale80.083,748300,1401,763,688Jan 05 06:08 PM
Krishnan Krish SPresident and CEOJan 03Sale80.331,700136,5671,767,436Jan 03 06:42 PM
Krishnan SumaPresident, R&DJan 03Sale80.331,700136,5671,767,436Jan 03 06:44 PM
Krishnan SumaPresident, R&DJan 03Sale80.331,700136,5541,706,201Jan 03 06:44 PM
Krishnan Krish SPresident and CEOJan 03Sale80.331,700136,5541,706,201Jan 03 06:42 PM
Krishnan SumaPresident, R&DDec 29Sale80.358,012643,7791,707,901Jan 03 06:44 PM
Krishnan Krish SPresident and CEODec 29Sale80.358,012643,7791,707,901Jan 03 06:42 PM
Krishnan SumaPresident, R&DDec 29Sale80.348,010643,5111,769,136Jan 03 06:44 PM
Krishnan Krish SPresident and CEODec 29Sale80.348,010643,5111,769,136Jan 03 06:42 PM
Krishnan Krish SPresident and CEODec 16Sale80.1010,572846,8161,777,146Dec 20 05:21 PM
Krishnan SumaPresident, R&DDec 16Sale80.1010,572846,8161,777,146Dec 20 05:23 PM
Krishnan SumaPresident, R&DDec 16Sale80.1010,527843,1701,715,913Dec 20 05:23 PM
Krishnan Krish SPresident and CEODec 16Sale80.1010,527843,1701,715,913Dec 20 05:21 PM
Krishnan SumaPresident, R&DNov 23Sale80.0143201,787,718Nov 28 06:26 PM
Krishnan Krish SPresident and CEONov 23Sale80.0143201,787,718Nov 28 06:24 PM
Krishnan Krish SPresident and CEONov 08Sale80.0596677,3311,787,722Nov 10 05:01 PM
Krishnan SumaPresident, R&DNov 08Sale80.0596677,3311,787,722Nov 10 05:05 PM
Krishnan SumaPresident, R&DNov 08Sale80.0482365,8711,726,440Nov 10 05:05 PM
Krishnan Krish SPresident and CEONov 08Sale80.0482365,8711,726,440Nov 10 05:01 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2023 FINVIZ.com. All Rights Reserved.